Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
Paula Rodríguez‐Otero(Clinica Universidad de Navarra), Sergio Giralt(Memorial Sloan Kettering Cancer Center), Bertrand Arnulf(Université Paris Cité), Ajay K. Nooka(Emory University), Ravi Vij(Washington University in St. Louis), Salomon Manier(Université de Lille), Natalie S. Callander(University of Wisconsin–Madison), Sikander Ailawadhi(Jacksonville College), Anna Truppel-Hartmann(Université Paris Cité), Jesús G. Berdeja(Tennessee Oncology), Linda Favre‐Kontula(Université Paris Cité), Mark Cook(Université Paris Cité), Krina K. Patel(University of Vermont), Nizar J. Bahlis(Institute of Cancer Research), Michèle Cavo(Unknown), Fan Wu(Quanzhou Normal University), Michel Delforge(KU Leuven), Philippe Moreau(Centre National de la Recherche Scientifique), Julia Piasecki(Université Paris Cité), Luciano J. Costa(University of Alabama at Birmingham), Zhihong Yang, Scott R. Solomon(Northside Hospital)
Cited by 695
Related Papers
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k